Abstract
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have